4.6 Article

Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/NXI.0000000000001014

关键词

-

资金

  1. FRM (Fondation pour la recherche medicale) [DQ20170336751]
  2. French National Research Agency (ANR), second Investissements d'Avenir program [ANR-18-RHUS-0012]
  3. Wellcome Trust [104079/Z/14/Z]
  4. European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases [739543]
  5. UCBOxford University Alliance
  6. BMA Research Grant-Vera Down grant (2013)
  7. BMA Research Grant-Margaret Temple (2017)
  8. Epilepsy Research UK [P1201]
  9. Fulbright UK-US commission (MS-Society research award)
  10. NIHR Oxford Biomedical Research Centre

向作者/读者索取更多资源

The updated diagnostic criteria for PNS proposed by a panel of experts involve the classification of high-risk, intermediate-risk, and low-risk phenotypes, as well as the introduction of a new classification of evidence for PNS.
Objective The contemporary diagnosis of paraneoplastic neurologic syndromes (PNSs) requires an increasing understanding of their clinical, immunologic, and oncologic heterogeneity. The 2004 PNS criteria are partially outdated due to advances in PNS research in the last 16 years leading to the identification of new phenotypes and antibodies that have transformed the diagnostic approach to PNS. Here, we propose updated diagnostic criteria for PNS. Methods A panel of experts developed by consensus a modified set of diagnostic PNS criteria for clinical decision making and research purposes. The panel reappraised the 2004 criteria alongside new knowledge on PNS obtained from published and unpublished data generated by the different laboratories involved in the project. Results The panel proposed to substitute classical syndromes with the term high-risk phenotypes for cancer and introduce the concept of intermediate-risk phenotypes. The term onconeural antibody was replaced by high risk (>70% associated with cancer) and intermediate risk (30%-70% associated with cancer) antibodies. The panel classified 3 levels of evidence for PNS: definite, probable, and possible. Each level can be reached by using the PNS-Care Score, which combines clinical phenotype, antibody type, the presence or absence of cancer, and time of follow-up. With the exception of opsoclonus-myoclonus, the diagnosis of definite PNS requires the presence of high- or intermediate-risk antibodies. Specific recommendations for similar syndromes triggered by immune checkpoint inhibitors are also provided. Conclusions The proposed criteria and recommendations should be used to enhance the clinical care of patients with PNS and to encourage standardization of research initiatives addressing PNS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据